Rigel Pharmaceuticals Inc Conference Call to Discuss VEPPANU (vepdegestrant) Licensing Agreement Transcript
Greetings. Welcome to RIGEL Pharmaceuticals BEPA New Licensing Agreement Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press *0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce our first speaker, Ray Fury, RIGEL's Executive Vice President. General Counsel, and Corporate Secretary.
Thank you, Mr. Ferry. You may begin.
Welcome to our conference call to discuss Rigel's in-licensing of Vepenu or Vepdecrant. The press release announcing the transaction was issued earlier this morning and can be viewed along with the slides for this presentation in the News and Events section of Investor Relations site on rigel.com.
As a reminder, during today's call, we may make forward-looking statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
